Huayi Li

机构：Tongji Hospital, Huazhong University of Science and Technology · ORCID：0000-0002-1161-4943

发表论文 93 篇 · 总被引 1708 次 · h-index 18

代表论文

• PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities (2023 · Drug Discovery Today · 被引 53)
• Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial (2024 · The Lancet Oncology · 被引 31)
• Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies (2024 · Molecular Cancer · 被引 26)
• New insights into the stemness of adoptively transferred T cells by γc family cytokines (2023 · Cell Communication and Signaling · 被引 17)
• SOCS3 inhibiting JAK-STAT pathway enhances oncolytic adenovirus efficacy by potentiating viral replication and T-cell activation (2023 · Cancer Gene Therapy · 被引 13)
• Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy (2025 · Science Translational Medicine · 被引 12)